薬理学用語集
薬理学、化学、臨床用語の総合用語集です。
A
Area Under the Curve (AUC)
(AUC)
Pharmacokinetics
Abbreviated New Drug Application (ANDA)
(ANDA)
Clinical
Adverse Drug Reaction (ADR)
(ADR)
Clinical
Accelerated Approval
Regulatory
Absorption Rate Constant (Ka)
(Ka)
Pharmacokinetics
Autoinduction
Pharmacokinetics
Allosteric Modulator (PAM/NAM)
(PAM/NAM)
Pharmacodynamics
Amorphous Solid
Chemistry
Adverse Event (AE)
(AE)
Clinical
Antibody-Drug Conjugate (ADC)
(ADC)
Research
ABC Transporter Superfamily (ABC)
(ABC)
Transporters
ATC Classification (ATC)
(ATC)
General
Angiotensin-Converting Enzyme (ACE)
(ACE)
Targets & Receptors
Antimetabolite
Immunopharmacology
Anaphylaxis
Immunopharmacology
Autoimmune Disease Therapy
Immunopharmacology
ADMET Prediction (ADMET)
(ADMET)
Computational Pharmacology
Agonist
Pharmacodynamics
ADME (ADME)
(ADME)
Chemistry
Antagonist
Pharmacodynamics
B
Bioavailability (F)
(F)
Pharmacokinetics
Breakthrough Therapy Designation (BTD)
(BTD)
Regulatory
Biologics License Application (BLA)
(BLA)
Research
Biosimilar
Research
Bioequivalence (BE)
(BE)
Clinical
Blinding
Clinical
BCRP (BCRP)
(BCRP)
Transporters
BSEP (BSEP)
(BSEP)
Transporters
Bioisostere
Chemistry
Biologic Response Modifier (BRM)
(BRM)
Immunopharmacology
Black Box Warning (BBW)
(BBW)
Regulatory
Binding Free Energy (delta-G)
(delta-G)
Computational Pharmacology
S
Steady State (Css)
(Css)
Pharmacokinetics
Selectivity
Pharmacodynamics
SMILES (SMILES)
(SMILES)
Chemistry
Salt Form
Chemistry
Structure-Activity Relationship (SAR)
(SAR)
Research
Spare Receptors
Pharmacodynamics
Signal Transduction
Pharmacodynamics
Second Messenger
Pharmacodynamics
Stereoisomer
Chemistry
Solubility
Chemistry
Salt Selection
Chemistry
Serious Adverse Event (SAE)
(SAE)
Clinical
Surrogate Endpoint
Clinical
Systems Pharmacology (QSP)
(QSP)
Computational Pharmacology
I
Inverse Agonist
Pharmacodynamics
InChI (InChI)
(InChI)
Chemistry
IUPAC Nomenclature (IUPAC)
(IUPAC)
Chemistry
International Council for Harmonisation (ICH)
(ICH)
Regulatory
Investigational New Drug Application (IND)
(IND)
Regulatory
Irreversible Antagonist
Pharmacodynamics
Immunostimulant
Immunopharmacology
Intrinsic Activity (alpha)
(alpha)
Pharmacodynamics
Informed Consent (IC)
(IC)
Clinical
Intention-to-Treat Analysis (ITT)
(ITT)
Clinical
International Nonproprietary Name (INN)
(INN)
General
IND-Enabling Studies
Research
Immunotoxicity
Toxicology
Immunosuppressant
Immunopharmacology
Interleukin (IL)
(IL)
Immunopharmacology
Ion Channel
Targets & Receptors
Immunoglobulin Therapy (IVIG)
(IVIG)
Immunopharmacology
H
Half Maximal Effective Concentration (EC50)
(EC50)
Pharmacodynamics
Half Maximal Inhibitory Concentration (IC50)
(IC50)
Pharmacodynamics
High-Throughput Screening (HTS)
(HTS)
Research
Hepatic Clearance (CLh)
(CLh)
Pharmacokinetics
Henderson-Hasselbalch Equation
Chemistry
Hydrogen Bond (H-bond)
(H-bond)
Chemistry
Hydrophobicity
Chemistry
Hepatotoxicity
Toxicology
Hit-to-Lead (H2L)
(H2L)
Research
Half-Life (t1/2)
(t1/2)
Pharmacokinetics
HMG-CoA Reductase (HMGCR)
(HMGCR)
Targets & Receptors
Hypersensitivity Reaction
Immunopharmacology
Homology Modeling
Computational Pharmacology
Hepatic Extraction Ratio (ER)
(ER)
Pharmacokinetics
E
Efficacy (Emax)
(Emax)
Pharmacodynamics
European Medicines Agency (EMA)
(EMA)
Regulatory
Enzyme Induction
Pharmacokinetics
Extraction Ratio (E)
(E)
Pharmacokinetics
Enantiomer
Chemistry
Excipient
General
ENT1 (ENT1)
(ENT1)
Transporters
Enzyme Target
Targets & Receptors
Enzyme Inhibition
Pharmacokinetics
Enterohepatic Recirculation
Pharmacokinetics
P
Potency
Pharmacodynamics
Partition Coefficient (LogP)
(LogP)
Chemistry
Phase I Clinical Trial
Clinical
Phase III Clinical Trial
Clinical
Pharmacogenomics (PGx)
(PGx)
Research
Plasma Protein Binding Displacement
Pharmacokinetics
Population Pharmacokinetics (PopPK)
(PopPK)
Pharmacokinetics
Partial Agonist
Pharmacodynamics
Phase II Clinical Trial
Clinical
Phototoxicity
Toxicology
pKa (pKa)
(pKa)
Chemistry
Placebo Effect
Clinical
Post-Marketing Surveillance (PMS)
(PMS)
Regulatory
Pediatric Exclusivity
Regulatory
Per-Protocol Analysis (PP)
(PP)
Clinical
Priority Review
Regulatory
PROTAC (PROTAC)
(PROTAC)
Research
Phenotypic Screening
Research
Preclinical Studies
Research
Pharmacovigilance (PV)
(PV)
General
P-glycoprotein (P-gp)
(P-gp)
Transporters
PEPT1 (PEPT1)
(PEPT1)
Transporters
Protease Inhibitor (PI)
(PI)
Targets & Receptors
Phosphodiesterase (PDE)
(PDE)
Targets & Receptors
Pharmacophore Modeling
Computational Pharmacology
PK/PD Modeling (PK/PD)
(PK/PD)
Computational Pharmacology
Polypharmacy
Clinical
Phase IV Clinical Trial
Clinical
Prodrug
Chemistry
Pharmacodynamics (PD)
(PD)
Pharmacodynamics
Physiologically Based Pharmacokinetics (PBPK)
(PBPK)
Computational Pharmacology
Protein Binding
Pharmacokinetics
Pharmacokinetics (PK)
(PK)
Pharmacokinetics
T
Tachyphylaxis
Pharmacodynamics
Topological Polar Surface Area (TPSA)
(TPSA)
Chemistry
Therapeutic Drug Monitoring (TDM)
(TDM)
Clinical
Tolerance
Pharmacodynamics
Target Validation
Research
Teratogenicity
Toxicology
Therapeutic Window
Toxicology
Toll-Like Receptor (TLR)
(TLR)
Targets & Receptors
Trough Concentration (Cmin)
(Cmin)
Pharmacokinetics
Tumor Necrosis Factor (TNF)
(TNF)
Immunopharmacology
Therapeutic Index (TI)
(TI)
Pharmacodynamics
Time to Maximum Concentration (Tmax)
(Tmax)
Pharmacokinetics
C
Chirality
Chemistry
Cytochrome P450 (CYP450)
(CYP450)
Toxicology
Controlled Substance
General
Compartment Model
Pharmacokinetics
Cross-Tolerance
Pharmacodynamics
Competitive Antagonist
Pharmacodynamics
Ceiling Effect
Pharmacodynamics
Crystalline Polymorphism
Chemistry
Co-Crystal
Chemistry
Crossover Design
Clinical
Compassionate Use
Regulatory
CRISPR Drug Discovery (CRISPR)
(CRISPR)
Research
Cardiotoxicity
Toxicology
Carcinogenicity
Toxicology
Constitutive Activity
Targets & Receptors
Clearance (CL)
(CL)
Pharmacokinetics
Cyclooxygenase (COX)
(COX)
Targets & Receptors
Checkpoint Inhibitor (ICI)
(ICI)
Immunopharmacology
CAR-T Cell Therapy (CAR-T)
(CAR-T)
Immunopharmacology
Cytokine Storm (CRS)
(CRS)
Immunopharmacology
Calcineurin Inhibitor (CNI)
(CNI)
Immunopharmacology
Complement Inhibitor
Immunopharmacology
Cheminformatics
Computational Pharmacology
N
Number Needed to Treat (NNT)
(NNT)
Clinical
Number Needed to Harm (NNH)
(NNH)
Clinical
No Observed Adverse Effect Level (NOAEL)
(NOAEL)
Toxicology
Non-Competitive Antagonist
Pharmacodynamics
Nocebo Effect
Clinical
Nuclear Receptor (NR)
(NR)
Targets & Receptors
Narrow Therapeutic Index (NTI)
(NTI)
General
Network Pharmacology
Computational Pharmacology
Neurotoxicity
Toxicology
New Drug Application (NDA)
(NDA)
Clinical
Non-Linear Pharmacokinetics
Pharmacokinetics
Nephrotoxicity
Toxicology
R
Randomized Controlled Trial (RCT)
(RCT)
Clinical
Risk Evaluation and Mitigation Strategy (REMS)
(REMS)
Regulatory
Renal Clearance (CLr)
(CLr)
Pharmacokinetics
Racemic Mixture
Chemistry
Regulatory Exclusivity
Regulatory
Relative Risk Reduction (RRR)
(RRR)
Clinical
Route of Administration
General
Receptor Tyrosine Kinase (RTK)
(RTK)
Targets & Receptors
Receptor Downregulation
Targets & Receptors
Receptor Upregulation
Targets & Receptors
Receptor Trafficking
Targets & Receptors
Receptor Dimerization
Targets & Receptors
Receptor Occupancy (RO)
(RO)
Pharmacodynamics
Receptor Desensitization
Pharmacodynamics
D
Drug-Drug Interaction (DDI)
(DDI)
Clinical
Drug-Induced Liver Injury (DILI)
(DILI)
Toxicology
Defined Daily Dose (DDD)
(DDD)
General
Dose Escalation
Clinical
Dose-Limiting Toxicity (DLT)
(DLT)
Clinical
Drug Master File (DMF)
(DMF)
Regulatory
Drug Candidate
Research
Dose-Response Assessment
Toxicology
Dosage Form
General
Drug Delivery System (DDS)
(DDS)
General
De Novo Drug Design
Computational Pharmacology
Drug-Likeness Score
Computational Pharmacology
Dose-Response Curve
Pharmacodynamics
Drug Repurposing
Research
G
O
Orphan Drug Designation (ODD)
(ODD)
Regulatory
OTC Monograph
Regulatory
Orphan Receptor
Targets & Receptors
OATP1B3 (OATP1B3)
(OATP1B3)
Transporters
OAT1 (OAT1)
(OAT1)
Transporters
OAT3 (OAT3)
(OAT3)
Transporters
OCT1 (OCT1)
(OCT1)
Transporters
OCT2 (OCT2)
(OCT2)
Transporters
Off-Label Use
Clinical
OATP1B1 (OATP1B1)
(OATP1B1)
Transporters
L
M
Maximum Tolerated Dose (MTD)
(MTD)
Toxicology
Michaelis-Menten Kinetics
Pharmacokinetics
Molecular Weight (MW)
(MW)
Chemistry
Metabolite
Chemistry
Margin of Safety (MOS)
(MOS)
Toxicology
Medication Adherence
General
Medication Error
General
MRP1 (MRP1)
(MRP1)
Transporters
MRP2 (MRP2)
(MRP2)
Transporters
MATE1 (MATE1)
(MATE1)
Transporters
MATE2-K (MATE2-K)
(MATE2-K)
Transporters
Monoclonal Antibody (mAb)
(mAb)
Immunopharmacology
mTOR Inhibitor
Immunopharmacology
Molecular Docking
Computational Pharmacology
Molecular Dynamics Simulation (MD)
(MD)
Computational Pharmacology
Machine Learning in Drug Discovery (ML)
(ML)
Computational Pharmacology
Maximum Plasma Concentration (Cmax)
(Cmax)
Pharmacokinetics
Metabolic Ratio (MR)
(MR)
Pharmacokinetics
Maintenance Dose
Pharmacokinetics